Endometrial cancer: The management of high-risk disease

Current Oncology Reports

Volumn 6, Issue 6, 2004, Pages 471-475

  Kristensen, Gunnar ^a   Tropé, Claes ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLINE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; PACLITAXEL; PROTEIN BCL 2;

ABDOMINAL TUMOR; ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLEAR CELL CARCINOMA; ENDOMETRIUM CANCER; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HYSTERECTOMY; LYMPH NODE DISSECTION; MYOMETRIUM; PARAAORTIC LYMPH NODE; PELVIS LYMPH NODE; PROGNOSIS; REVIEW; RISK ASSESSMENT; SALPINGOOOPHORECTOMY; STROMA; SURGICAL TECHNIQUE; SURVIVAL TIME; TREATMENT INDICATION; TREATMENT PLANNING; UTERINE CERVIX; UTERUS CARCINOMA;

EID: 9744279083     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-004-0078-2     Document Type: Review

References (34)

1. Creasman WT, Odicino F, Maisonneuve P, et al.: Carcinoma of the corpus uteri. J Epidemiol Biostat 2001, 6: 5-86.
2. Creasman WT, Morrow CP,, Bundy BN, et al.: Surgical pathologic spread patterns of endometrial cancer: a Gynecologic Oncology Group Study. Cancer 1987, 60:2035-2041.
3. Goff BA, Kato D, Schmidt RA, et al.: Uterine papillary serous carcinoma: patterns of metastatic spread. Gynecol Oncol 1994, 54:264-268.
4. Cirisano FD, Robboy SJ, Dodge RK, et al.: Epidemiologic and surgicopathologic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinoma. Gynecol Oncol 1999, 74:385-394.
5. Abeler VM, Vergote IB, Kjørstad KE, et al.: Clear cell carcinoma of the endometrium: prognosis and metastatic pattern. Cancer 1996, 78:1740-1747.
6. Wu W, Slomovitz BM, Celestino J, et al.: Coordinate expression of Cdc25B and ER-alpha is frequent in low-grade endometrioid endometrial carcinoma but uncommon in high-grade endometrioid and nonendometrioid carcinomas. Cancer Res 2003, 63:6195-6199.
7. Nordstrom B, Strang P, Bergstrom R, et al.: A comparison of proliferation markers and heir prognostic value for women with endometrial carcinoma. Ki-67, proliferating cell nuclear antigen, and flow cytometric S-phase fraction. Cancer 1996, 78: 942-1951.
8. Geisler JP, Geisler HE, Wiemann MC, et al.: Lack of bcl-2 persistence: an independent prognostic indicator of poor prognosis in endometrial carcinoma. Gynecol Oncol 1998, 71:305-307.
9. Levine DA, Hoskins WJ: Update in the management of endometrial cancer. Cancer 2002, 8:S31-S40.
10. Herbst AL: Endometrial hyperplasia, endometrial carcinoma, sarcoma: diagnosis and management. In Comprehensive Gynecology, edn 4. Edited by Stenchever MA, Droegemueller W, Herbst AL, et al. St. Louis, MO: Mosby; 2001:919-954.
11. Mariani A, Webb MJ, Keeney GL, et al.: Role of wide/radical hysterectomy and pelvic lymph node dissection in endometrial cancer with cervical involvement. Gynecol Oncol 2001, 83: 2-80.
12. Sartori E, Gadducci A, Landoni F, et al.: Clinical behavior of 203 stage II endometrial cancer cases: the impact of primary surgical approach and of adjuvant radiation therapy. Int J Gynecol Cancer 2001, 11:430-437.
13. Cornelison TL, Trimble EL, Kosary CL: SEER data, corpus uteri cancer: treatment trends versus survival for FIGO stage II, 1988-1994. Gynecol Oncol 1999, 74:350-355.
14. Onda T, Yoshikawa H, Mizutani K, et al.: Treatment of node-positive endometrial cancer with complete node dissection, chemotherapy and radiation therapy. Br J Cancer 1997, 75: 836-1841.
15. Corn BW, Lanciano RM, Greven KM, et al.: Endometrial cancer with para-aortic adenopathy: patterns of failure and opportunities for cure. Int J Radiat Oncol Biol Phys 1992, 24:223-227.
16. Kilgore LC, Partridge EE, Alvarez RD, et al.: Adenocarcinoma of the endometrium: survival comparisons of patients with and without pelvic node sampling. Gynecol Oncol 1995, 56: 9-33.
17. Bristow RE, Zerbe MJ, Rosenshein NB, et al.: Stage IVB endometrial carcinoma: the role of cytoreductive surgery and determinants of survival. Gynecol Oncol 2000, 78:85-91.
18. Goff BA, Goodman A, Muntz HG, et al.: Surgical stage IV endometrial carcinoma: a study of 47 cases. Gynecol Oncol 1994, 52:237-240.
19. Aalders J, Abeler V, Kolstad P, et al.: Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients. Obstet Gynecol 1980, 56:419-427.
20. Creutzberg CL, van Putten WL, Koper PC, et al.: Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet 2000, 355:1404-1411.
21. Greven KM, Lanciano RM, Corn B, et al.: Pathologic stage III endometrial carcinoma: prognostic factors and patterns of recurrence. Cancer 1993, 71:3697-3702.
22. Mariani A, Webb MJ, Keeney GL, et al.: Stage IIIC endometrioid corpus cancer includes distinct subgroups. Gynecol Oncol 2002, 87:112-117.
23. Nelson G, Randall M, Sutton G, et al.: FIGO stage IIIC endometrial carcinoma with metastases confined to pelvic lymph nodes: analysis of treatment outcomes, prognostic variables, and failure patterns following adjuvant radiation therapy. Gynecol Oncol 1999, 75:211-214.
24. Hicks ML, Piver MS, Puretz JL, et al.: Survival in patients with paraaortic lymph node metastases from endometrial adenocarcinoma clinically limited to the uterus. Int J Radiat Oncol Biol Phys 1993, 26:607-611.
25. Rose PG, Cha SD, Tak WK, et al.: Radiation therapy for surgically proven para-aortic node metastasis in endometrial carcinoma. Int J Radiat Oncol Biol Phys 1992, 24:229-233.
26. Connell PP, Rotmensch J, Waggoner S, et al.: The significance of adnexal involvement in endometrial carcinoma. Gynecol Oncol 1999, 74:74-79.
27. Ashman JB, Connell PP, Yamada D, et al.: Outcome of endometrial carcinoma patients with involvement of the uterine serosa. Gynecol Oncol 2001, 82:338-343.
28. Nicklin JL, Petersen RW: Stage 3B adenocarcinoma of the endometrium: a clinicopathologic study. Gynecol Oncol 2000, 78:203-207.
29. Randall ME, Brunetto VL, Muss H, et al.: Whole abdominal radiotherapy versus combination doxorubicin-cisplatin chemotherapy in advanced endometrial carcinoma: a randomized phase III trial of the Gynecologic Oncology Group [abstract]. Proc ASCO 2003, 22:2.
30. Fleming GF, Brunetto VL, Cella D, et al.: Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 2004, 22:2159-2166.
31. Sutton G, Bundy B, Axelrod J, et al.: Whole-abdominal radiotherapy in stage I- and II papillary serous (PS) or clear cell cancers of the uterus (a GOG study) [abstract 192]. Gynecol Oncol 2002, 85:535.
32. Rosenberg P, Boeryd B, Simonsen E: A new aggressive treatment approach to high-grade endometrial cancer of possible benefit to patients with stage I uterine papillary cancer. Gynecol Oncol 1993, 48:32-37.
33. Price FV, Chambers SK, Carcangiu ML, et al.: Intravenous cisplatin, doxorubicin, and cyclophosphamide in the treatment of uterine papillary serous carcinoma (UPSC). Gynecol Oncol 1993, 51:383-389.
34. Levenback C, Burke TW, Silva E, et al.: Uterine papillary serous carcinoma (UPSC) treated with cisplatin, doxorubicin, and cyclophosphamide (PAC). Gynecol Oncol 1992, 46: 17-321.